Utilize este identificador para referenciar este registo:
https://hdl.handle.net/1822/61777
Registo completo
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Vieira, Raquel | por |
dc.contributor.author | Souto, Selma B. | por |
dc.contributor.author | Sánchez-López, Elena | por |
dc.contributor.author | Machado, Ana López | por |
dc.contributor.author | Severino, Patricia | por |
dc.contributor.author | Jose, Sajan | por |
dc.contributor.author | Santini, Antonello | por |
dc.contributor.author | Fortuna, Ana | por |
dc.contributor.author | García, Maria Luisa | por |
dc.contributor.author | Silva, Amelia M. | por |
dc.contributor.author | Souto, Eliana B. | por |
dc.date.accessioned | 2019-10-14T09:20:56Z | - |
dc.date.available | 2019-10-14T09:20:56Z | - |
dc.date.issued | 2019-10-10 | - |
dc.identifier.citation | Vieira, Raquel; Souto, Selma B.; Sánchez-López, Elena; Machado, Ana López; Severino, Patricia; Jose, Sajan; Santini, Antonello; Fortuna, Ana; García, Maria Luisa; Silva, Amelia M.; Souto, Eliana, Sugar-Lowering Drugs for Type 2 Diabetes Mellitus and Metabolic SyndromeReview of Classical and New Compounds: Part-I. Pharmaceuticals, 12(4), 152, 2019 | por |
dc.identifier.issn | 1424-8247 | por |
dc.identifier.uri | https://hdl.handle.net/1822/61777 | - |
dc.description.abstract | Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia together with disturbances in the metabolism of carbohydrates, proteins and fat, which in general results from an insulin availability and need imbalance. In a great number of patients, marketed anti-glycemic agents have shown poor effectiveness in maintaining a long-term glycemic control, thus being associated with severe adverse effects and leading to an emerging interest in natural compounds (e.g., essential oils and other secondary plant metabolites, namely, flavonoid-rich compounds) as a novel approach for prevention, management and/or treatment of either non-insulin-dependent diabetes mellitus (T2DM, type 2 DM) and/or Metabolic Syndrome (MS). In this review, some of these promising glucose-lowering agents will be comprehensively discussed. | por |
dc.description.sponsorship | This work was financially supported by the Portuguese Science and Technology Foundation (FCT/MCT) and from European Funds (PRODER/COMPETE) under the project reference M-ERANET/0004/2015-PAIRED and UID/AGR/04033/2019 (CITAB), co-financed by FEDER, under the Partnership Agreement PT2020, and also by the Institute of Nanoscience and Nanotechnology under the project ART(2018). | por |
dc.language.iso | eng | por |
dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | por |
dc.relation | UID/AGR/04033/2019 | por |
dc.rights | openAccess | por |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | por |
dc.subject | diabetes mellitus | por |
dc.subject | metabolic syndrome | por |
dc.subject | glucose-lowering agents | por |
dc.subject | sugar-lowering oils | por |
dc.subject | phytotherapy | por |
dc.title | Sugar-lowering drugs for type 2 diabetes mellitus and metabolic syndrome - review of classical and new compounds: Part-I | por |
dc.type | article | - |
dc.peerreviewed | yes | por |
dc.comments | CEB52077 | por |
oaire.citationIssue | 4 | por |
oaire.citationVolume | 12 | por |
dc.date.updated | 2019-10-12T11:11:03Z | - |
dc.identifier.doi | 10.3390/ph12040152 | por |
dc.description.publicationversion | info:eu-repo/semantics/publishedVersion | - |
dc.subject.wos | Science & Technology | por |
sdum.journal | Pharmaceuticals | por |
oaire.version | VoR | por |
Aparece nas coleções: | CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
document_52077_1.pdf | 925,88 kB | Adobe PDF | Ver/Abrir |
Este trabalho está licenciado sob uma Licença Creative Commons